Overview

Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Investigator's Choice of Standard Chemotherapy in Adults Receiving First Cytotoxic Chemotherapy for Metastatic or Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC) and Who Are C

Status:
Completed

Trial end date:
2020-02-21

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the safety and efficacy of veliparib plus carboplatin and paclitaxel versus the Investigator's choice of standard chemotherapy in adults with metastatic or advanced non-squamous non-small cell lung cancer.

Phase:

Phase 3

Details

Lead Sponsor:

AbbVie

Treatments:

Albumin-Bound Paclitaxel
Carboplatin
Cisplatin
Paclitaxel
Pemetrexed
Veliparib